Biosciences

CN Bio has licenced a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University to investigate the direct interaction between the microbiome and gut and the wider effects of the microbiome on organs such as the liver and brain. Planned for commercial launch in 2023, the technology […]

Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture. The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, […]

In this podcast John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines the benefits they create for […]

In this podcast John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines the benefits they create for […]

Listen to this article on the DDW Podcast: Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than 100 compounds. During the drug discovery process, […]

At an update to investors, GlaxoSmithKline (GSK) provided details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business. An equity research expert suggests that while targets are friendly, investors will not get a completely clean break from the new consumer business. […]

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new drug compounds to discover new […]

The Industrial Biotechnology Innovation Centre (IBioIC) has launched a Spin-Out Support Programme to provide funding for the commercialisation of industrial biotechnology concepts and the creation of spin-outs, helping drive the growth of Scotland’s bioeconomy. Funding will support researchers at Scottish universities to progress bio-based research and establish new companies, within two years of the grant […]

Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular. Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally combine biology and chemistry expertise […]

Neo Kuma Ventures has invested in seven innovative healthcare companies. The initial investments have proved successful with three of the seven companies going public this year, yielding between +180% and +680% return on initial investment. Following the launch of its fund in December 2020, Neo Kuma has invested more than £5 million across ATAI Life […]